CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Advances in Coronary No-Reflow Phenomenon-a Contemporary Review Coronary flow velocity reserve predicts adverse prognosis in women with angina and noobstructive coronary artery disease: resultsfrom the iPOWER study Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with) Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention
|<<... 16 17 18 19 20 21 22 ...>>|

Recommandation StatementFeb 13, 2020

JOURNAL：ACC Article Link

ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV)

ACC Keywords: COVID-19

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top